A Certified Reference Material
Features
  • This product is qualified as a Certified Reference Material (CRM) that has been manufactured and tested to meet ISO/IEC 17025 and ISO 17034 international standards
  • This CRM has been characterized by metrologically valid procedures and may be used as a quantitative analytical reference standard
  • Certificate of analysis provides the certified property values and the associated uncertainties, including a statement of metrological traceability for the certified values
  • Possession of a DEA Controlled Substance registration is not necessary nor is a DEA 222 form required to purchase this product
  • Bulk material is available for qualified institutions; please contact our sales department for pricing
Related Products
Unlabeled Version(s)
15554Diclazepam 28623Diclazepam (CRM)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Diclazepam-13C2-d4 (CRM)

A 100 µg/ml solution in acetonitrile

Item No. 43155

Exempt Product (US)
Safety Data Sheet (SDS) (PDF)
Synonyms
Synonyms
  • 2′-Chlorodiazepam-13C2-d4
Technical Information
Formal Name
7-chloro-5-(2-chlorophenyl-3,4,5,6-d4)- 1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one-2,3-13C2
Molecular Formula
C14[13C]2H8Cl2D4N2O
Formula Weight
325.2
Formulation (Request formulation change)
A 100 µg/ml solution in acetonitrile
SMILES
ClC1=CC(C(C2=C(Cl)C([2H])=C([2H])C([2H])=C2[2H])=N[13CH2]3)=C(C=C1)N(C)[13C]3=O
InChi Code
InChI=1S/C16H12Cl2N2O/c1-20-14-7-6-10(17)8-12(14)16(19-9-15(20)21)11-4-2-3-5-13(11)18/h2-8H,9H2,1H3/i2D,3D,4D,5D,9+1,15+1
InChi Key
VPAYQWRBBOGGPY-KUMQCNLBSA-N
Regulatory Information
DEA Exempt Notification
This product is a DEA exempt preparation of a scheduled compound - does not require DEA Controlled Substance registration or DEA 222 form. For alternate sizes please contact sales.
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 µg

    $169

    Add
    Cayman Chemical
    Forensic Lab Guide Wall Posters

    Discover our collection of drug identification, naming, and metabolism posters for your lab. We offer all of our posters at no cost to help support the forensic community.

    REQUEST YOURS
    Product Description

    Diclazepam-13C2-d4 (CRM) (Item No. 43155) is intended for use as an internal standard for the quantification of diclazepam (Item Nos. 28623 | 15554) by GC- or LC-MS. Diclazepam is categorized as a benzodiazepine. It has been found in illicit seized samples and has sedative properties.1,2 It is metabolized in vivo into delorazepam (Item Nos. 42198 | 15938), lorazepam (Item Nos. ISO60202 | 15891), and lormetazepam (Item Nos. 43236 | 21989).3 Diclazepam-13C2-d4 is regulated as a Schedule I compound in the United States. Diclazepam-13C2-d4 (CRM) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Jones, L.E., Stewart, A., Peters, K.L., et al. Infrared and raman screening of seized novel psychoactive substances: A large scale study of >200 samples. Analyst 141(3), 902-909 (2016).

    2. Abouchedid, R., Gilks, T., Dargan, P.I., et al. Assessment of the availability, cost, and motivations for use over time of the new psychoactive substances-benzodiazepines diclazepam, flubromazepam, and pyrazolam-in the UK. J. Med. Toxicol. 14(2), 134-143 (2018).

    3. Moosmann, B., Bisel, P., and Auwärter, V. Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test Anal. 6(7-8), 757-763 (2014).